Abbott LaboratoriesABTNYSE
Loading
Cash Generation ExpandingExpanding
Percentile Rank71
3Y CAGR-1.8%
5Y CAGR+5.3%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-1.8%/yr
vs +12.3%/yr prior
5Y CAGR
+5.3%/yr
Recent deceleration
Acceleration
-14.1pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.3x
Solid growth
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $7.39B | +16.4% |
| 2024 | $6.35B | +25.5% |
| 2023 | $5.06B | -35.2% |
| 2022 | $7.80B | -9.8% |
| 2021 | $8.65B | +51.1% |
| 2020 | $5.72B | +27.3% |
| 2019 | $4.50B | -8.3% |
| 2018 | $4.91B | +10.6% |
| 2017 | $4.43B | +113.0% |
| 2016 | $2.08B | - |